Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

Cancer Science

Volumn 106, Issue 7, 2015, Pages 896-901

  Ogura, Michinori ^a   Uchida, Toshiki ^a   Terui, Yasuhito ^b   Hayakawa, Fumihiko ^c   Kobayashi, Yukio ^d   Taniwaki, Masafumi ^e   Takamatsu, Yasushi ^f   Naoe, Tomoki ^g   Tobinai, Kensei ^d   Munakata, Wataru ^d   Yamauchi, Takeshi ^h   Kageyama, Akiko ^h   Yuasa, Miyuki ^h   Motoyama, Masaaki ^h   Tsunoda, Takeshi ^h   Hatake, Kiyohiko ^b  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Daily dosing schedule; Hematological malignancy; OPB 51602; Phase I study; STAT3 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; LACTIC ACID; OPB 51602; PROTEIN INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; STAT3 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROTEIN PROCESSING;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NERVOUS SYSTEM DISEASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT3 TRANSCRIPTION FACTOR;

EID: 84936985203     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12683     Document Type: Article

References (28)

1. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 2004; 22: 361-71.
2. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4(2): 97-105.
3. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007; 102: 311-9.
4. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54.
5. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-88.
6. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21.
7. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13: 211-7.
8. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-73.
9. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-72.
10. Silva CM. Role of STATs as downstream signal transducers in Src family kinase mediated tumorigenesis. Oncogene 2004; 23: 8017-23.
11. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB. Control of myeloid differentiation and survival by Stats. Oncogene 2000; 19: 2612-8.
12. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19: 2496-504.
13. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000; 19: 2523-31.
14. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci 2006; 1086: 213-22.
15. Bowman T, Broome MA, Sinibaldi D et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-24.
16. Turkson J, Ryan D, Kim JS et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276: 45443-55.
17. Leong PL, Andrews GA, Johnson DE et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 4138-43.
18. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007; 13: 5665-9.
19. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-73.
20. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-9.
21. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
22. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-20.
23. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14: 736-46.
24. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008; 18: 254-67.
25. Harrison C, Kiladjian J-J, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-98.
26. Verstovsek S, Mesa RA, Gotlib J et al. A double- blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
27. Rozovski U, Wu JY, Harris DM et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 2014; 123: 3797-802.
28. Goh BC, Wong ALA, Soo RA et al. Phase I study of OPB51602, a small molecule inhibitor of STAT3 phosphorylation, in patients with refractory solid malignancies. J Clin Oncol. 2012; 30: 173s, (abstr 3002).